About Ondine Biomedical
Ondine Biomedical is a publicly listed company based in Vancouver (Canada) founded in 1999 by Carolyn Cross. It operates as an anti-infective therapies are developed via light-activated Photodisinfection technology. Its chief executive is Carolyn Cross. Ondine Biomedical offers products and services including Steriwave and Photodisinfection Pipeline. Its focus areas include Life Sciences, Infectious Diseases, Medical Devices and Therapeutics. Its legal entity is Ondine Biomedical Inc. Its competitors include Cerus, Aethlon Medical, Amferia, Larada Sciences and 3Oe Scientific and 3 more; 5 of its 8 listed competitors have raised funding.
Company details
Founded in 1999 in Vancouver, Canada, anti-infective therapies targeting bacterial, viral, and fungal infections are developed and commercialized by the company. Patented Photodisinfection technology is utilized to provide antimicrobial effects without promoting antibiotic resistance. Operations center on applications in infection control, with the lead product being the MRSAid nasal decolonization system for methicillin-resistant Staphylococcus aureus in the nares. The biomedical sector is served through these innovations.
- Headquarters Vancouver, Canada
- Founders Carolyn Cross
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website ondinebio.com
- Social LinkedIn X Facebook
- Legal Name Ondine Biomedical, Inc.
- Annual Revenue$1.94 M (USD)22.76as on Dec 31, 2025
- Net Profit-$21.59 M (USD)-46.92as on Dec 31, 2025
- EBITDA-$21.48 M (USD)-47.92as on Dec 31, 2025
- Latest Funding Round$3.99M (USD), Post-IPO
Jan 2025
Products & Services of Ondine Biomedical
Ondine Biomedical offers a comprehensive portfolio of products and services, including Steriwave and Photodisinfection Pipeline.
Eradicates nasal pathogens to prevent healthcare-associated infections.
Develops therapies for wounds, sinuses, and respiratory issues.
Funding Insights of Ondine Biomedical
- Total Rounds 7
- Last Round Post-IPO — $3.99M
- First Round $480,183
(Jun 2009)
All 7 funding rounds of Ondine Biomedical with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2025 | $3.99M | Post-IPO | – | – | – |
| Nov 2024 | $12.74M | Post-IPO | – | – | – |
| Dec 2023 | – | Unspecified | – | – | – |
| Apr 2010 | $45,463 | Unspecified | – | – | – |
| Dec 2009 | $228,592 | Unspecified | – | – | – |
| Sep 2009 | $43,360 | Unspecified | – | – | – |
| Jun 2009 | $480,183 | Unspecified | – | – | – |
People of Ondine Biomedical
18 people are tracked at Ondine Biomedical (10 in leadership, 6 in board & advisors, 2 in team).
| Name | Role | Group |
|---|---|---|
Carolyn Cross | Founder & CEO | Leadership |
Angelika Vance | Vice President, Corporate Communication | Leadership |
Nicolas G. Loebel | President and Chief Technology Officer | Leadership |
Jason Hickok | Vice President, Clinical and Medical Affairs | Leadership |
Bill Kanz | Vice President, Engineering | Leadership |
Kwong Choo | VP, Finance | Leadership |
Matt Ross | VP, Sales & Marketing | Leadership |
Caetano Padial Sabino | Director Of Research And Development | Leadership |
Jeremy Kerr M.b | Director Of Sales | Leadership |
Nikita Parkhaev | Vice President Finance | Leadership |
Jean Charest | Chair | Board & advisors |
Simon Sinclair | Non-Executive Director | Board & advisors |
Jean Duval | Senior Independent Director | Board & advisors |
Junaid Bajwa | Non-Executive Director | Board & advisors |
Craig Tooman | Non-Executive Director | Board & advisors |
Mike Farrar | Non-Executive Director | Board & advisors |
Elaine Lei | Corporate Controller | Team |
Cristina Patricia Romo Bernal | Senior Scientist & Laboratory Manager | Team |
Complete people profiles for Ondine Biomedical
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Ondine Biomedical
Ondine Biomedical is a publicly listed company on the LSE with ticker symbol OBI in UK, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date06 Dec 2021
- Listed onLSE: OBI
- Listed entityOndine Biomedical, Inc.
- Exchange sectorHealth technology
- ISINCA68234M2058
- Share price9.75 GBX · 2026-09-29
- Market capitalisation54,718,767.00 GBX
- EPS (diluted, trailing year)-0.04 GBX
- Volume (last session)747,590
Financials of Ondine Biomedical
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 1.4M GBP | -16.0M GBP | -15.9M GBP |
| 2024 | 1.2M GBP | -10.9M GBP | -10.8M GBP |
| 2023 | 717,040 GBP | -8.6M GBP | -8.5M GBP |
| 2022 | 397,860 GBP | -12.1M GBP | -12.2M GBP |
| 2021 | 1.5M GBP | -29.1M GBP | -9.9M GBP |
Detailed financial statements for Ondine Biomedical
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Ondine Biomedical
4 dated milestones of Ondine Biomedical across 26 years, from founding to its latest funding, stage changes and deals.
- Founded Ondine Biomedical is founded.
- Funding First funding round of $480K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $4.0M.
Competitors of Ondine Biomedical
Ondine Biomedical has 8 listed competitors in our database, 5 of them funded. They include Cerus, Aethlon Medical, Amferia, Larada Sciences and 3Oe Scientific, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| cerus.com | 1991 | Concord, United States | – | 247 | Provider of pathogen inactivation technology for blood center or hospital blood bank | |
| aethlonmedical.com | 1999 | San Diego, United States | – | 14 | Hemopurification devices are developed to eliminate viruses and exosomes. | |
| amferia.com | 2018 | Gothenburg, Sweden | $3.45M | – | Anti-infective technology is developed using selective anti-bacterial polymers. | |
| laradasciences.com | 2006 | Salt Lake, United States | $2.63M | – | Head lice are removed by a network of certified professionals. | |
| 3oescientific.com | 2010 | Carmel, United States | $3.71M | – | Provider of smart solutions to manage pathogen infections | |
| toefx.com | 2016 | Hamilton, Canada | $30,000 | – | Treatments for toenail fungus are developed using photodynamic therapy. | |
| zappkit.com | 2007 | Hafnarfjordur, Iceland | – | – | Provides frequency therapy through mobile app and hardware for user health support. | |
| pathex.co | 2016 | Nashville, United States | $5M | – | Developing blood-cleansing device to remove pathogens from circulating blood |
Detailed competitors of Ondine Biomedical
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Ondine Biomedical
The website of Ondine Biomedical (ondinebio.com) receives about 2.7K visits a month.
- Monthly visits2.7K
▲ 42% vs previous month
Top companies in Infectious Diseases
10 companies that operate in the same segment as Ondine Biomedical (Infectious Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 | |
Clinical diagnostics and drug discovery for immune diseases are provided. | 2009 | Seattle, Washington, United States | USD 419.15 M | USD 276.98 M | 619 | |
Vaccines for infectious diseases are developed using cell-free protein synthesis. | 2013 | Foster City, California, United States | USD 347 M | – | 414 | |
Portable PCR diagnostics for infectious diseases are developed. | 2010 | San Jose, California, United States | USD 386.33 M | – | 172 | |
Developing glucan synthase inhibitors for the treatment of fungal infections. | 1999 | Jersey City, New Jersey, United States | USD 62.65 M | USD 20.6 M | 28 | |
Sherlock Biosciences is focused on molecular diagnostics development. | 2019 | Watertown, United States | USD 111 M | – | 33 | |
Provider of diagnostic solutions for systemic infections | 2016 | San Francisco, California, United States | USD 191.47 M | – | 54 | |
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | – | 329 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ondine Biomedical
Complete news archive for Ondine Biomedical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ondine Biomedical
Ondine Biomedical was founded in 1999 and raised its 1st funding round 10 years after it was founded.
Ondine Biomedical is headquartered in Vancouver, Canada. It is registered at Vancouver, British Columbia, Canada.
Carolyn Cross is the current CEO of Ondine Biomedical. They have also founded this company.
Annual revenue of Ondine Biomedical is $1.94M as on Dec 31, 2025.
Founded in 1999 in Vancouver, Canada, anti-infective therapies targeting bacterial, viral, and fungal infections are developed and commercialized by the company. Patented Photodisinfection technology is utilized to provide antimicrobial effects without promoting antibiotic resistance. Operations center on applications in infection control, with the lead product being the MRSAid nasal decolonization system for methicillin-resistant Staphylococcus aureus in the nares. The biomedical sector is served through these innovations.
Ondine Biomedical's top competitors include Cerus, Aethlon Medical and PATH EX.
Ondine Biomedical offers Steriwave and Photodisinfection Pipeline.
Yes, Ondine Biomedical is publicly traded on LSE under the ticker symbol OBI.
Ondine Biomedical operates through Ondine Biomedical Inc..